Download - GLOBAL VACCINE MARKET PLACE
22
Estimated 2013 Global Vaccine Market $32 Billion
2013 US Vaccine Market for the 78 Licensed Vaccines was ~ $13.2 Billion; combination of 1/3rd Adult and 2/3rd Children (Pediatric & Adolescents)• CDC recommends an immunization schedule for persons aged 0 – 18
years of age totaling 14 vaccines• CDC recommends an immunization schedule for Adults of 11 vaccines
Global Vaccine Market is estimated to grow to over $84 Billion by 2022 backed by advances in technology and vaccines towards emerging infectious diseases, cancers and allergies; leading to personalized vaccine treatments.• Projected growth rate of 10-15% per year versus 5 – 7% for
Pharmaceuticals. • More than 295 vaccines in various phases of development by 102
Companies.
33
Global Vaccine Market GAP
In 1990, 1 in 100 children died before reaching five years of age; by 2002 that rate had improved to 1 in 143. Scandinavian countries enjoy the lowest rate of child mortality* Source: Unicef
Developing Countries
85%
93%
Vaccine Sales 82% 18%
Source: WHO
Population 15%
BoD 7%
36 Industrialised Countries Developing Countries
85%
93%
Vaccine Sales 82% 18%
Source: WHO
Population 15%
BoD 7%
36 Industrialised Countries
66
Vaccines are Becoming an Engine for the Pharmaceutical Industry
Resulting in:• Growing concentration in the 34 OECD countries• Newer and more expensive vaccines are coming into the market• Vaccine development: increasing Investment for industrialized markets• New business model for vaccines are emerging in developing countries: Manufacturer & Country Partnerships,
Risk sharing with countries and funders, Increased presence of Sales forces like the Pharma model
77
US FDA Licensed VaccinesManufacturer and their number of Vaccines
Sponsor Count
Sanofi Pasteur, Inc 25GlaxoSmithKline Biologicals 13
Merck & Co, Inc 12Novartis Vaccines and Diagnostics Ltd 6ID Biomedical Corporation of Quebec 4
MedImmune, LLC 3CSL Limited 2
Organon Teknika Corp LLC 2Wyeth Pharmaceuticals Inc 2
Barr Labs, Inc. 1Berna Biotech, Ltd 1
BioPort Corp(not available) 1Emergent BioDefense Operations Lansing Inc. 1
Greer Laboratories Inc. (not available) 1Intercell Biomedical 1
MassBiologics 1Protein Sciences Corporation 1
Research Foundation for Microbial Diseases of Osaka University 1
Total 78NB: Products are listed in the Appendix
1313
Pipeline and Marketed Influenza Vaccine’s
Sources: Assistant Secretary for Preparedness and Response
1515
Production types of Seasonal and Pandemic Influenza Vaccines
Production types1. Egg based: 99.8% of 2013
doses2. VLP: Medicago, Novavax,
Technovax3. Recombinant Proteins: Protein
Sciences
4. Cell-derived: Novartis
5. Viral Vectors
6. DNA
1717
Manufacturers to supply 139.25 M Seasonal Flu Vaccine doses for the 2014
2014 Manufacturers1. Sanofi Pasteur: 60M doses
a. Quadravalent
2. Novartis: 30M dosesa. Quadravalent will be available only for
Flucelvax , site transferred from Marburg, Germany
3. GSK: 22 – 24M dosesa. Quadravalent will be available only
with Fluarix (10 M doses from Germany)
4. Medimmune: 13 – 15Ma. Quadravalent
5. CSL: 10M
6. Protein Sciences: 0.250M
2020
Pandemic Vaccine preparedness; May 2009 H1N1 experience
• The World Population is 6.84 Billion People living in 206 countries. • The World production capacity for each of the vaccines, Pandemic and Seasonal
Influenza, is ~876 Million doses produced by ~36 manufacturers. • Actual vaccine output has many factors; two key drivers are (1) The viral strains
selected by the World Health Organization and (2) The platform technology used to manufacture vaccine.
• Once vaccines are produced; Countries draw against this capacity in different ways. – The chart below shows the H1N1 Pandemic Vaccine by segment: